Clinical Trials
Clinical Trial Tracker
Registered trials of peptide compounds, with phase, recruitment status, sponsor, enrollment, and primary endpoints. Search or filter to find any tracked trial.
Showing 3,711 of 3,711 tracked trials
- NCT07586150N/ANot Yet Recruiting
Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
- Compound
- Semaglutide
- Sponsor
- Ludwig-Maximilians - University of Munich
- Enrollment
- 140
- Started
- Oct 2028
- NCT07382375N/ANot Yet Recruiting
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
- Compound
- Thymosin-Alpha-1
- Sponsor
- Nanjing Medical University
- Enrollment
- 300
- Started
- Dec 2027
- NCT07797036Phase 2/Phase 3Not Yet Recruiting
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
- Compound
- Semaglutide
- Sponsor
- University of Massachusetts, Worcester
- Enrollment
- 226
- Started
- Sep 2027
- NCT07430332Phase 2Not Yet Recruiting
GLP-1 RA for Stage 1 Type 1 Diabetes
- Compound
- Semaglutide
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Enrollment
- 15
- Started
- Sep 2027
- NCT06303284Phase 1/Phase 2Not Yet Recruiting
PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot)
- Compound
- Teriparatide
- Sponsor
- University of Calgary
- Enrollment
- 54
- Started
- Mar 2027
- NCT07265752Phase 2Not Yet Recruiting
Tirzepatide for the Treatment of Cannabis Use Disorder
- Compound
- Tirzepatide
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 6
- Started
- Mar 2027
- NCT07711548N/ANot Yet Recruiting
Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity?
- Compound
- Semaglutide
- Sponsor
- Knut Mai
- Enrollment
- 292
- Started
- Mar 2027
- NCT07754045Phase 2Not Yet Recruiting
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
- Compound
- Semaglutide
- Sponsor
- Lumos Pharma
- Enrollment
- 202
- Started
- Feb 2027
- NCT07847515N/ANot Yet Recruiting
Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients
- Compound
- Tirzepatide
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
- Enrollment
- 80
- Started
- Feb 2027
- NCT05714683N/ANot Yet Recruiting
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- Compound
- Semaglutide
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 600
- Started
- Jan 2027
- NCT07879612Phase 2Not Yet Recruiting
Semaglutide for the Treatment of Cannabis Use Disorder
- Compound
- Semaglutide
- Sponsor
- Massachusetts General Hospital
- Enrollment
- 40
- Started
- Jan 2027
- NCT07803250Phase 1Not Yet Recruiting
Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery
- Compound
- BPC-157
- Sponsor
- University of Arkansas
- Enrollment
- 30
- Started
- Jan 2027
- NCT07622992N/ANot Yet Recruiting
Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery
- Compound
- Tirzepatide
- Sponsor
- Mario Musella MD
- Enrollment
- 96
- Started
- Jan 2027
- NCT07787936N/ANot Yet Recruiting
GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry
- Compound
- Tirzepatide
- Sponsor
- Miedziowe Centrum Zdrowia SA
- Enrollment
- 150
- Started
- Jan 2027
- NCT07614412Phase 2Not Yet Recruiting
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.
- Compound
- Semaglutide
- Sponsor
- Ministry of Health, Saudi Arabia
- Enrollment
- 240
- Started
- Jan 2027
- NCT07858331Phase 4Not Yet Recruiting
Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
- Compound
- Semaglutide
- Sponsor
- Kristin Clemens
- Enrollment
- 880
- Started
- Jan 2027
- NCT06558422Phase 1Not Yet Recruiting
Human Models of Selective Insulin Resistance: Pancreatic Clamp
- Compound
- Octreotide
- Sponsor
- Columbia University
- Enrollment
- 36
- Started
- Jan 2027
- NCT07829198Phase 3Not Yet Recruiting
Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Compound
- Tirzepatide
- Sponsor
- Universidade do Porto
- Enrollment
- 70
- Started
- Jan 2027
- NCT07078838Phase 2Not Yet Recruiting
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
- Compound
- Tirzepatide
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Enrollment
- 40
- Started
- Jan 2027
- NCT07706361N/ANot Yet Recruiting
Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults
- Compound
- GHK-Cu
- Sponsor
- LifeWave, Inc.
- Enrollment
- 100
- Started
- Jan 2027
- NCT07859319Phase 4Not Yet Recruiting
Evaluation of the Efficacy and Acceptability of a Phytotherapy Combining Devil's Claw, Blackcurrant and Meadowsweet for the Management of Aromatase Inhibitor-induced Arthralgia in Patients Treated for Localized Breast Cancer in the Adjuvant Setting
- Compound
- Gonadorelin
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 105
- Started
- Jan 2027
- NCT07889648Phase 3Not Yet Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
- Compound
- Tirzepatide
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 948
- Started
- Dec 2026
- NCT07770282Phase 3Not Yet Recruiting
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
- Compound
- Semaglutide
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
- Enrollment
- 600
- Started
- Dec 2026
- NCT06180616Phase 2Not Yet Recruiting
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
- Compound
- Tirzepatide
- Sponsor
- Royal North Shore Hospital
- Enrollment
- 40
- Started
- Dec 2026
- NCT07881432Phase 3Not Yet Recruiting
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
- Compound
- Tirzepatide
- Sponsor
- Eli Lilly and Company
- Enrollment
- 2,115
- Started
- Dec 2026
- NCT07790861Phase 3Not Yet Recruiting
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
- Compound
- Orforglipron
- Sponsor
- Eli Lilly and Company
- Enrollment
- 192
- Started
- Dec 2026
- NCT07842172Phase 3Not Yet Recruiting
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
- Compound
- Octreotide
- Sponsor
- Washington University School of Medicine
- Enrollment
- 240
- Started
- Nov 2026
- NCT07468552Phase 2Not Yet Recruiting
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
- Compound
- Tirzepatide
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Enrollment
- 100
- Started
- Nov 2026
- NCT07803705N/ANot Yet Recruiting
Efficacy of Mazdutide on Fatty Pancreas
- Compound
- Mazdutide
- Sponsor
- Tongji Hospital
- Enrollment
- 194
- Started
- Nov 2026
- NCT07884201Phase 2Not Yet Recruiting
Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment
- Compound
- Thymosin-Alpha-1
- Sponsor
- Fudan University
- Enrollment
- 572
- Started
- Nov 2026